The US Food and Drug Administration (FDA) has granted accelerated approval to Vimkunya™, a recombinant chikungunya vaccine, ...

Insights from Prothena's Q4 2024 call highlight 2025 milestones: pivotal trial results for birtamimab & Alzheimer's programs.

Four new SPMS patients not eligible for a Tiziana Life Sciences trial were dosed with foralumab nasal spray in an expanded access program.

The WHO has orchestrated two mass vaccination campaigns during pauses of fighting in the ongoing war between Israel and Hamas.

SAN DIEGO, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today reported its fourth quarter and full year 2024 financial results and provided a corporate update.

Currently More Than 400 Clinical Trials Studies Are Active In Saudi Arabia Says Kuick Research In New Research ReportDelhi, ...

Key achievements included positive Phase 3 ASPEN data for brensocatib in bronchiectasis, record-breaking ARIKAYCE revenues, and advancements in other pipeline programs such as TPIP and ARIKAYCE's ...

Study did not demonstrate statistically significant improvement on primary endpoint of reduction in depressive symptoms as measured by MADRS total score compared to placeboSPN-820 was well-tolerated ...

Bantam Pharmaceutical, a drug discovery and development company targeting selective modulation of mitochondrial dynamics in ...

Ionis relies on upfront payments and licensing fees from partners, as well as Spinraza royalties, to drive revenue today, but its rapidly advancing portfolio should help diversify revenue. 2025 is ...

Krystal Biotech KRYS reported fourth-quarter earnings per share of $1.52, which beat the Zacks Consensus Estimate of $1.29 as ...